Prof. Dr. Péter Hamar obtained his DSc from the Hungarian Academy of Sciences in 2011, Specialization in Clinical Laboratory Medicine in 2001, Ph.D. in 1999, and MD in 1994 at Semmelweis University. He received part of his scientific training at the Immune Disease Institute of Harvard Medical School, Boston, MA, USA, where he was a Fullbright Sholar and the University Clinic, Essen, and Heidelberg, Germany as a recipient of DAAD scholarships. Presently, he is a professor of medicine at Semmelweis University Institute of Translational Medicine. He is also medical director at Corden Laboratories International, Hungary. His scientific interest is to understand the pathophysiologic role of locally produced acute phase proteins (lAPR), especially of fibrinogen in vivo with mouse models of modulated electrohyperthermia (mEHT) treated triple negative breast cancer (TNBC) and ischemia-induced renal fibrosis.
Prof. Dr. Péter Hamar obtained his DSc from the Hungarian Academy of Sciences in 2011, Specialization in Clinical Laboratory Medicine in 2001, Ph.D. in 1999, and MD in 1994 at Semmelweis University. He received part of his scientific training at the Immune Disease Institute of Harvard Medical School, Boston, MA, USA, where he was a Fullbright Sholar and the University Clinic, Essen, and Heidelberg, Germany as a recipient of DAAD scholarships. Presently, he is a professor of medicine at Semmelweis University Institute of Translational Medicine. He is also medical director at Corden Laboratories International, Hungary. His scientific interest is to understand the pathophysiologic role of locally produced acute phase proteins (lAPR), especially of fibrinogen in vivo with mouse models of modulated electrohyperthermia (mEHT) treated triple negative breast cancer (TNBC) and ischemia-induced renal fibrosis.